A5025515809- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Restless Legs Syndrome Research
- Sleep and Wakefulness Research
- Botulinum Toxin and Related Neurological Disorders
- Autism Spectrum Disorder Research
- Dementia and Cognitive Impairment Research
- Sleep and related disorders
- Neurological diseases and metabolism
- Genetic Neurodegenerative Diseases
- Neurobiology of Language and Bilingualism
- Lysosomal Storage Disorders Research
- Nuclear Receptors and Signaling
- Ginkgo biloba and Cashew Applications
- Alzheimer's disease research and treatments
- Attention Deficit Hyperactivity Disorder
- Olfactory and Sensory Function Studies
- Cerebral Palsy and Movement Disorders
- Balance, Gait, and Falls Prevention
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Chemical Sensor Technologies
- Voice and Speech Disorders
- Functional Brain Connectivity Studies
- Pharmacological Effects and Toxicity Studies
- Biochemical Analysis and Sensing Techniques
University of Pittsburgh
2018-2025
American University of Beirut
2006-2025
University of Pennsylvania
2012-2024
University of Iowa
2020-2024
Rutgers, The State University of New Jersey
2024
Georgetown University
2021-2024
University of Rochester
2009-2024
University of Colorado Anschutz Medical Campus
2024
Radboud University Medical Center
2023
Pittsburg State University
2023
Abstract Objective The Parkinson's Progression Markers Initiative ( PPMI ) is an observational, international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, genetic, biospecimen disease PD progression markers accelerate disease‐modifying therapeutic trials. Methods A total of 423 untreated , 196 Healthy Control HC 64 SWEDD (scans without evidence dopaminergic deficit) subjects were enrolled at 24 sites. To enroll as early possible following diagnosis,...
Abstract This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD). Background Both CI NPS are common PD impact course quality life. However, limited knowledge is available about abilities NPS. Methods Progression Markers Initiative (PPMI) a multi‐site healthy controls (HCs), latter normal cognition. At baseline, participants were assessed neuropsychological...
To report the rates and predictors of progression from normal cognition to either mild cognitive impairment (MCI) or dementia using standardized neuropsychological methods.A prospective cohort patients diagnosed with Parkinson disease (PD) baseline was assessed for decline, performance, function a minimum 2 years, up 6. A panel movement disorders experts classified as having cognition, MCI, dementia, 55/68 (80.9%) eligible seen at year Kaplan-Meier curves Cox proportional hazard models were...
ABSTRACT Objective: The objective of this study was to assess longitudinal change in clinical and dopamine transporter imaging outcomes early, untreated PD. Methods: We describe 5‐year the MDS‐UPDRS other measures using results from Parkinson's Progression Markers Initiative, a cohort early disease (PD) participants at baseline. also provide data on 123‐I Ioflupane striatal binding correlation between 2 measures. Results: A total 423 PD were recruited, 358 remain year 5. Baseline score 32.4...
Background: The effect of the COVID-19 pandemic on people with Parkinson’s disease (PD) is poorly understood. Objective: To rapidly identify areas need and improve care in PD during pandemic, we deployed a survey to assess symptoms pandemic’s among those without COVID-19. Methods: People participating online study Fox Insight (FI) were invited complete between April 23 May 23, 2020. Among reporting diagnoses, compared outcomes PD. not COVID-19, assessed access healthcare services symptoms....
Abstract Background The objective of this study was to assess neurofilament light chain as a Parkinson's disease biomarker. Methods We quantified in 2 independent cohorts: (1) longitudinal cerebrospinal fluid samples from the de novo cohort and (2) large with serum disease, other cognate/neurodegenerative disorders, healthy controls, prodromal conditions, mutation carriers. Results In Progression Marker Initiative cohort, mean baseline higher patients (13 ± 7.2 pg/mL) than controls (12 6.7...
To analyze longitudinal levels of CSF biomarkers in drug-naive patients with Parkinson disease (PD) and healthy controls (HC), examine the extent to which these biomarker changes relate clinical measures PD, identify what may influence them.CSF α-synuclein (α-syn), total phosphorylated tau (t- p-tau), β-amyloid 1-42 (Aβ42) were measured at baseline 6 12 months 173 PD 112 matched HC international multicenter Parkinson's Progression Marker Initiative. Baseline demographic variables,...
Objectives To assess the neurobiological substrate of initial cognitive decline in Parkinson's disease (PD) to inform patient management, clinical trial design, and development treatments. Methods We longitudinally assessed, up 3 years, 423 newly diagnosed patients with idiopathic PD, untreated at baseline, from 33 international movement disorder centers. Study outcomes were four determinations impairment or decline, biomarker predictors baseline dopamine transporter (DAT) single photon...
Biochemical abnormalities present in GBA (mut/wt) carriers may offer new pathogenetic insights to and potential therapeutic targets Parkinson disease (PD).To determine whether patients having PD with vs without mutations differ clinical phenotype or plasma protein expression.Case-control study of mutations. Clinical characteristics were compared between groups, biochemical profiling 40 proteins was performed identify that differed expression groups.The discovery cohort included 20...
The Systemic Synuclein Sampling Study (S4) measured α-synuclein in multiple tissues and biofluids within the same patients with Parkinson disease (PD) vs healthy controls (HCs).S4 was a 6-site cross-sectional observational study of participants early, moderate, or advanced PD HCs. Motor nonmotor measures dopamine transporter SPECT were obtained. Biopsies skin, colon, submandibular gland (SMG), CSF, saliva, blood collected. Tissue biopsy sections stained 5C12 monoclonal antibody against...
ABSTRACT Cognitive impairment is one of the earliest, most common, and disabling non‐motor symptoms in Parkinson's disease (PD). Thus, routine screening global cognitive abilities important for optimal management PD patients. Few instruments have been developed or validated The Mini‐Mental State Examination (MMSE), Montreal Assessment (MoCA), Dementia Rating Scale‐2 (DRS‐2) used extensively both clinical research settings. Determining how to convert scores between would facilitate...
To examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) a prospective cohort of, at baseline, patients with de novo Parkinson's disease (PD) compared healthy controls (HC).Parkinson's Progression Markers Initiative (PPMI) is longitudinal, ongoing, controlled study of PD participants HC. NMS were rated using Movement Disorder Society Unified Disease Rating Scale (MDS-UPDRS) Part I score other validated scales after 2 years. Biological variables included...
Abstract Background Aggregation of α‐synuclein is central to the pathophysiology PD. Biomarkers related may be informative for PD diagnosis/progression. Objectives To analyze in CSF drug‐naïve PD, healthy controls, and prodromal Parkinson's Progression Markers Initiative. Methods Over up 36‐month follow‐up, total its association with MDS‐UPDRS motor scores, cognitive assessments, dopamine transporter imaging were assessed. Results The inception cohort included (n = 376; age [mean {standard...
Abstract Objectives The Parkinson Associated Risk Syndrome Study identified a cohort of healthy adults with hyposmia and dopamine transporter binding reduction to characterize individuals at risk for Parkinson's disease (PD). We describe the cognitive profile this cohort. Methods Individuals older than 50 y without PD were recruited. Two hundred twenty‐five completed testing included in final analysis. A neuropsychological test battery was administered normative scores created global...
Abstract Objective This study was undertaken to determine the frequency and correlates of excessive daytime sleepiness in de novo, untreated Parkinson's disease (PD) patients compared with matched healthy controls. Methods Data were obtained from Progression Markers Initiative, an international PD At baseline, participants assessed a wide range motor nonmotor scales, including Movement Disorder Society Unified Disease Rating Scale (MDS‐UPDRS). Excessive based on Epworth Sleepiness scale...